A Study of SEA-CD40 Given with Other Drugs in Cancers (Melanoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called SEA-CD40 is a safe and effective treatment for melanoma when it's given in combination with pembrolizumab.

What is the Condition Being Studied?


Who Can Participate in the Study?

Adults ages 18+ who:
- Are diagnosed with melanoma and have not gotten better after 3 rounds of therapy that include an anti-PD-(L)1 monoclonal antibody; OR
- Are diagnosed with metastatic uveal melanoma; OR
- Are diagnosed with metastatic melanoma and have never received an anti-PD-(L)1 monoclonal antibody

For more information about who can be in this study, please contact the study team at carolann.wiggs@duke.edu

Age Group

What is Involved?

If you choose to join this study, you will:
- Get the study drug, SEA-CD40, through a vein in your arm (IV) every 6 weeks
- Get pembrolizumab through IV every 3 weeks
- Have physical exams
- Have blood draws
- Give urine samples
- Have regular MRI or CT scans during the study
- Possibly have a needle biopsy of your tumor

You will receive the study drugs for up to 2 years unless you have unwanted side effects or the study doctor finds that you are not getting better.

Study Details

Full Title
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00108587
NCT: NCT04993677
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center